
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Overview | Financials
Company Name | Vertex Pharmaceuticals Incorporated |
Symbol | VRTX |
Currency | USD |
Price | 504.77 |
Market Cap | 129,619,888,300 |
Dividend Yield | 0% |
52-week-range | 377.85 - 519.88 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Reshma Kewalramani FASN, M.D. |
Website | https://www.vrtx.com |
An error occurred while fetching data.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD
